Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Novo Nordisk Arms Wegovy to Be a Triple Threat
marketbeat.com0 Comments
There are no comments on this post yet.